Arthritis can be a debilitating condition that can leave sufferers unable to work and care for their family. A Social Security disability attorney can help you determine if you are eligible to receive Social Security disability benefits.
The Food & Drug Administration (FDA) has now approved medication for arthritis patients. The makers of this new medication, AstraZeneca and POZEN Inc., have developed a fixed-dose combination of a pain-relieving non-steroidal anti-inflammatory drug.
VIMOVO TM (naproxen and esomeprazole magnesium) is supposed to help give relief to those who are suffering from the symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It comes in a delayed-response tablet and should also help reduce the chance of developing gastric ulcers for patients who are at risk of this.
Osteoarthritis is the most common type of arthritis with about 27 million people in the United States suffering from it. There are some common risk factors in developing osteoarthritis which include:
If you or someone you love suffers from a severe physical or mental condition, you may be eligible to receive Social Security disability benefits. A Social Security disability attorney can help you understand your rights and determine if you may be eligible for disability benefits.
Don't go it alone! The attorneys at LaVan & Neidenberg, located in Atlanta, Georgia, understand the inner workings of the Social Security Administration and will help you navigate the system. Call us today for a FREE legal consultation - 1-888-234-5758.
You want the upper-hand on your Social Security Disability claim - don't you? Then request a FREE copy of our publication Secrets Social Security Won't Tell You to learn valuable insider tips on how you can increase the chances of winning your claim. This report normally sells for $14.95 but we will send it to you at no cost if you ACT NOW!
Post a Comment to "FDA Approves Medication for Arthritis Patients"
To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."